Publication, Part of Cancer Survival in England
Cancer Survival in England, cancers diagnosed 2018 to 2022, followed up to 2023
National statistics, Accredited official statistics
Replaced the lifetables file with correct IMD labelling.
15 April 2026 13:41 PM
Summary
This release summarises the survival of adults aged 15 to 99 years diagnosed with cancer in England between 2018 and 2022 with follow-up to the end of 2023.
Adult cancer survival estimates are presented by cancer group, age at diagnosis, deprivation, gender, stage at diagnosis, hormone receptor status (Breast only), and health geography.
The estimates presented below and in the main report are age-standardised net survival. Some of the net survival estimates are over 100%. This means fewer people are dying than would be expected in the general population.
Highlights
What is new?
- National Disease Registration Service (NDRS) cancer groups are now used to present survival estimates (previously based solely on ICD-10) for adult cancers. The groups are defined using either ICD-O-2, ICD-O-3, or ICD-10 depending on the cancer group. The data presented is a combination of both the NDRS main and NDRS detailed cancer groups.
- National adult cancer survival estimates are presented for 103 NDRS cancer groups by age, gender and hormone receptor status (Breast only). Survival estimates are also presented by deprivation quintile.
- Adult cancer survival estimates by stage are presented for 43 NDRS cancer groups.
- Adult cancer survival estimates are presented for 43 NDRS cancer groups for each Government office region (GOR), Cancer alliance (CA) and Integrated care board (ICB).
Upcoming statistics
-
Childhood cancer survival estimates for 2018 to 2022 followed up to 2023.
-
Cancer survival estimates for adults and children diagnosed with cancer between 2020 and 2024, followed up to the end of 2025. We will be publishing updated lifetables based on the new Index of Multiple Deprivation 2025, along with a re-calculated back series of adult and childhood cancer survival estimates for rolling 5-year cohorts from 2013 to 2017.
Please sign up to our newsletter for further updates and exact timeframes for publications.
Key Facts
Cancer survival in males and females is highest for basal cell carcinoma
Basal cell carcinoma had the highest survival at five years after diagnosis for males (101.1%) and females (102.4%).
Cancer survival in males is high for cutaneous squamous cell carcinoma, prostate cancer, melanoma and cancer of the testes
Excluding basal cell carcinoma, 1-year survival in males is highest for cutaneous squamous cell carcinoma (97.7%), prostate cancer (97.4%), melanoma (97.2%), and cancer of the testes (95.2%). 5-year survival is highest for cancer of the testes (94.9%), cutaneous squamous cell carcinoma (90.4%), melanoma (89.7%), and prostate cancer (89.5%).
Cancer survival in females is high for melanoma, cutaneous squamous cell carcinoma, breast cancer and follicular lymphoma
Excluding basal cell carcinoma, 1-year survival in females is highest for melanoma (98.5%), cutaneous squamous cell carcinoma (98.1%), breast cancer (96.2%), and follicular lymphoma (95.5%). 5-year survival is highest for melanoma (94.3%), cutaneous squamous cell carcinoma (93.4%), thyroid cancer (90.6%), and breast cancer (86.8%).
Cancer survival is lowest for cancer of the pancreas
Cancer of the pancreas had the lowest survival at both one and five years after diagnosis for both males (29.5% and 9.4%) and females (29.5% and 9.3%).
Cancer survival varies by stage at diagnosis
Survival at five years after diagnosis for lung cancer in males is 59.6% for stage 1 and 4.2% for stage 4. For prostate cancer, survival is 102.3% for stage 1 and 54.8% for stage 4.
Cancer survival is lower in areas with higher deprivation
For most cancers, survival is generally lower in patients diagnosed in areas that are the most deprived and higher in areas that are the least deprived.
Acknowledgements
This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of the National Disease Registration Service (NDRS) in NHS England.
Data sets
Data tables are available as an OpenDocument spreadsheet (ODS) file. Lifetables from 2002 to 2024 are also available as an ODS file.
Resources
Last edited: 15 April 2026 1:41 pm